EXPLORATORY STUDY TO EVALUATE THE SAFETY AND EFFICACY OF CD07387 SOLUTION IN PATIENTS WITH VITILIGO

GALDERMA R&D0 个研究点目标入组 36 人开始时间: 2010年9月27日最近更新: 2022年4月4日

试验速览

暂无简介。

•Subjects who meet the following key inclusion criteria may be eligible for the study:
•The subject is a male or a female, aged 18 to 65 years old inclusive.
•The female subject should be of non childbearing potential, i.e. female presenting with hysterectomy or bilateral ovariectomy, or having a bilateral tubal ligation, or postmenopausal female (absence of menses for at least 1 year without an alternative medical cause).
•The subject has a clinical diagnosis of non-segmental (generalized) symmetrical vitiligo, with stable plaques on the trunk for more than 3 months (no change in pigmentation or size over the last 3 months for the plaque(s) to be treated).
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Any subject who meets one or more of the following key exclusion criteria will not be included in the study:
•The subject has an underlying known disease, a surgical or medical condition (i.e. cardiovascular, endocrinological, psychatric, neurological,...) that, in the opinion of the investigator might put the subject at risk.
•The subject has an underlying dermatological disease (i.e.: history of atopic dermatitis, eczema, psoriasis), which, in the judgment of the investigator, could interfere with the study assessments.

发起方